GGCX抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-4: LO2, Hela, 293T, 231 cell lysates, Primary antibody: P01404(GGCX Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P01404(GGCX Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

The gamma-glutamyl carboxylase (GGCX) antibody is a tool used to detect and study GGCX, a critical enzyme in the vitamin K-dependent post-translational modification of proteins. GGCX catalyzes the carboxylation of specific glutamate residues in target proteins, enabling their calcium-binding capacity—a process essential for the activation of coagulation factors (e.g., factors II, VII, IX, X), anticoagulant proteins (e.g., protein C, S), and bone-related proteins (e.g., osteocalcin). Dysregulation of GGCX is linked to bleeding disorders, osteoporosis, and pseudoxanthoma elasticum (PXE)-like syndromes.

GGCX antibodies are primarily used in research to investigate enzyme expression, localization, and function in tissues like the liver (main site of coagulation factor synthesis) and bone. They facilitate techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Polyclonal and monoclonal antibodies have been developed, with varying specificity across species (human, mouse, rat). Challenges in antibody development stem from GGCX’s hydrophobic transmembrane domains and low cellular abundance.

Clinically, GGCX autoantibodies are rare but implicated in autoimmune-related coagulopathies. Research on GGCX antibodies also explores genetic mutations causing vitamin K-dependent clotting factor deficiencies (VKCFD) and their role in metabolic bone diseases. These studies advance understanding of hemostasis, vascular calcification, and therapeutic strategies targeting vitamin K pathways.